Tagged with access,

Switzerland Switzerland, rightly regarded as one of the world’s most innovative nations, risks damaging its reputation if innovative new medicines continue to face significant delays and roadblocks in their introduction to the domestic Swiss market. Key stakeholders from pharma industry associations Interpharma and scienceindustries and local affiliate heads for multinationals Bayer…

USA Executives from ALK, Sanofi Genzyme and Novartis discuss how they are navigating pricing and reimbursement issues in the USA, home to the world’s largest – but perhaps most complex – pharmaceutical market.   While the sheer dominance of the US market – the largest in the world, accounting for around…

Covid-19 The South African affiliate of Indian pharma firm Cipla will begin manufacturing and distribution of remdesivir, a Covid-19 drug, in South Africa this month. The company’s priority is ensuring access to vulnerable populations in emerging markets.     Cipla South Africa has been granted a license to manufacture and distribute remdesivir,…

USA Ulrich Neumann examines the debate around drug pricing in the US and why it is not going away any time soon.   Come senators, congressmen Please heed the call Don’t stand in the doorway Don’t block up the hall For he that gets hurt Will be he who has stalled”…

China Dr Qing Liu, Arctic Vision’s VP for Clinical & Regulatory Affairs, shares her key priorities and the potential for top-line ophthalmological innovations in the Chinese market.   Unmet medical needs in eye care are huge in the Asia markets, and biotech companies will become increasingly important players and innovation drivers…

Novartis In late 2019 Novartis hit the headlines in Belgium after it refused to grant access to its one-off gene therapy Zolgensma® for the ultra-rare muscle-wasting disease spinal muscular atrophy (SMA) to Pia Boehnke, a Belgian child.   With Zolgensma® at that point having not yet been authorised by the European…

Opinion Pharmaceutical innovation is racing ahead of the US health system’s ability to adjust payment models, but innovative concepts are finally emerging. We will have to move beyond siloed thinking to establish them for the sake of getting patients sustainable access to a new wave of transformative cures, argues Ulrich Neumann.…

Vaccines Jeremy Farrar, director of the Wellcome Trust, spoke to Financial Times correspondent Vanessa Kortekaas on 25 June 2020 about the global race to develop a COVID-19 vaccine. He emphasized the importance of prioritising access to at-risk populations, supply chain scale issues that must be considered, why there is no future…

Belgium Veronique Walsh, General Manager of Bristol Myers Squibb (BMS) – Benelux, explains her ambition to build a new company culture following the acquisition of Celgene. Walsh also lays bare the prospects for bringing innovation to Belgian patients and explains how BMS continues to deliver on its promise of transforming lives…

Europe Emmanuel Macron and Angela Merkel recently put their heads together to come up with a health strategy that would ensure greater European access to innovative medicines and COVID-19 treatments.   The so-called “power couple” – German chancellor Angela Merkel and French president Emmanuel Macron –  presented a jointly developed five-point…

USA Jorge Alderete, president of ALK Americas, outlines the Danish mid-cap’s strategy in the challenging US market, including innovative market access initiatives, and how future models of patient-doctor interaction and medical distribution will look.   Affordability is key. We recently launched a specialty pharmacy network for our portfolio. This allows us…

Romania Mirela Iordan country manager of Pfizer Romania reveals some of her milestones, including integrating new acquisitions and setting up the first financial centre in Europe for Pfizer. She shares her insights on how the affiliate is working to maximise patients’ access to the latest innovations through patient assistance programs, early…